Weidong Han

20.2k total citations · 6 hit papers
267 papers, 15.0k citations indexed

About

Weidong Han is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Weidong Han has authored 267 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Oncology, 98 papers in Molecular Biology and 67 papers in Immunology. Recurrent topics in Weidong Han's work include CAR-T cell therapy research (86 papers), Immune Cell Function and Interaction (42 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Weidong Han is often cited by papers focused on CAR-T cell therapy research (86 papers), Immune Cell Function and Interaction (42 papers) and Cancer Immunotherapy and Biomarkers (32 papers). Weidong Han collaborates with scholars based in China, United States and Philippines. Weidong Han's co-authors include Yao Wang, Xiaobing Fu, Zhiqiang Wu, Yelei Guo, Hanren Dai, Xiaolei Li, Kaichao Feng, Jiejie Liu, Haojie Hao and Chuan Tong and has published in prestigious journals such as Science, The Lancet and Nucleic Acids Research.

In The Last Decade

Weidong Han

258 papers receiving 14.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

2020 940 citations Yao Wang, Weidong Han et al. profile →
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

2020 719 citations Meixia Chen, Yan Zhang et al. profile →
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b

2015 547 citations Dongdong Ti, Chuan Tong et al. profile →
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

2020 293 citations Na Tang, Chen Cheng et al. JCI Insight profile →
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer

2021 253 citations Kaichao Feng, Weidong Han et al. profile →
Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation

2024 83 citations Weidong Han et al. profile →

Peers

Countries citing papers authored by Weidong Han

Since Specialization

Citations

This map shows the geographic impact of Weidong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidong Han more than expected).

Fields of papers citing papers by Weidong Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weidong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidong Han. The network helps show where Weidong Han may publish in the future.

Co-authorship network of co-authors of Weidong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Weidong Han. A scholar is included among the top collaborators of Weidong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weidong Han. Weidong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epi‐Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future Directions 2025 ·PubMed ·(unknown), Guanghua Rong, Weidong Han	0
2	CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation 2025 ·Cellular and Molecular Immunology ·(unknown), (unknown), (unknown), Lu Han, Zhiqiang Wu, Yao Wang, Xin Lin, Jianshu Wei, Weidong Han	1
3	Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy 2024 ·International Immunopharmacology ·(unknown), (unknown), (unknown), Yang Liu, Meng Zhang, Xia Xiao, Hairong Lyu, Juanxia Meng, Haibo Zhu, Kailin Xu, Weidong Han, Mingfeng Zhao	6
4	Manganese boosts natural killer cell function via cGAS–STING mediated UTX expression 2024 ·SHILAP Revista de lepidopterología ·(unknown), Jiejie Liu, (unknown), Tiance Wang, (unknown), Yan Zhang, Meixia Chen, Yingli Sun, Weidong Han, Qian Mei	5
5	Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial 2024 ·Nature Communications ·Liang Dong, Zhi Cao, Meixia Chen, Yang Liu, Xinran Ma, Yuting Lu, Yan Zhang, Kaichao Feng, Yang Zhang, (unknown), Qingming Yang, Yao Wang, Zhiqiang Wu, Weidong Han	7
6	Construction of a predictive model for osteoporosis risk in men: using the IOF 1-min osteoporosis test 2023 ·Journal of Orthopaedic Surgery and Research ·K. Zhang, Min Wang, Weidong Han, Weihong Yi, (unknown)	2
7	IL-6 translation is a therapeutic target of human cytokine release syndrome 2023 ·The Journal of Experimental Medicine ·Yuzhuo Yang, (unknown), (unknown), (unknown), Xin Lin, Yao Wang, (unknown), Chunmeng Wang, Bin Zhang, Weidong Han, Xiaoyu Hu	14
8	Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma 2023 ·Signal Transduction and Targeted Therapy ·Yao Wang, Chuan Tong, Yuting Lu, Zhiqiang Wu, Yelei Guo, Yang Liu, Jianshu Wei, Chunmeng Wang, Qingming Yang, Weidong Han	35
9	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy 2021 ·Clinical Cancer Research ·Chunmeng Wang, Yang Liu, Liang Dong, Xiang Li, Qingming Yang, Malcolm V. Brock, Qian Mei, Jiejie Liu, Meixia Chen, Fengxia Shi, Miao Liu, Jing Nie, Weidong Han	29
10	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial 2021 ·Leukemia ·(unknown), Yao Wang, Yang Liu, Chuan Tong, Chunmeng Wang, Yelei Guo, Dongdong Ti, Qingming Yang, (unknown), Zhiqiang Wu, Weidong Han	64
11	Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done? 2021 ·Cellular and Molecular Immunology ·Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Wenbin Qian, Aibin Liang, Weidong Han	1
12	Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study 2020 ·Journal for ImmunoTherapy of Cancer ·Kaichao Feng, Yang Liu, (unknown), Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han	89
13	TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors breakdown → 2020 ·JCI Insight ·Na Tang, Chen Cheng, Xingying Zhang, Miaomiao Qiao, Na Li, Wei Mu, Xiaofei Wei, Weidong Han, Haoyi Wang	293
14	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial 2020 ·Clinical Cancer Research ·Qian Mei, Wenying Zhang, Yang Liu, Qingming Yang, John E.J. Rasko, Jing Nie, Jiejie Liu, Xiang Li, Liang Dong, Meixia Chen, Yan Zhang, Lu Shi, (unknown), Weidong Han	17
15	Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy 2017 ·Clinical Cancer Research ·Xiang Li, Yan Zhang, Meixia Chen, Qian Mei, Yang Liu, Kaichao Feng, Hejin Jia, Liang Dong, Lu Shi, Lin Liu, Jing Nie, Weidong Han	45
16	Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers 2017 ·Clinical Cancer Research ·Yelei Guo, Kaichao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Hejin Jia, Weidong Han	196
17	Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial 2016 ·Clinical Cancer Research ·Chunmeng Wang, Zhiqiang Wu, Yao Wang, Yelei Guo, Hanren Dai, Xiaohui Wang, Xiang Li, (unknown), Wenying Zhang, Meixia Chen, Yan Zhang, Kaichao Feng, Yang Liu, Su‐Xia Li, Qingming Yang, Weidong Han	261
18	Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway 2016 ·Clinical Cancer Research ·Qian Mei, Xiang Li, Kang Zhang, Zhiqiang Wu, Xiaolei Li, Yuanguang Meng, Mingzhou Guo, Guangbin Luo, Xiaobing Fu, Weidong Han	30
19	Relationships between plasma homocysteine level and both recurrence and mortality in patients with acute ischemic stroke 2016 ·Chinese Journal of Neuromedicine ·Wei Yue, Hao Wu, Zhihong Shi, Weidong Han, Hui Wang, Xin Li, Lin Wang, Yong Ji	1
20	Clinicopathological significance of LRP16 protein in 336 gastric carcinoma patients 2009 ·World Journal of Gastroenterology ·(unknown), Po Zhao, Weidong Han	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact